Stock TVGN TEVOGEN BIO HOLDINGS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Tevogen Bio Holdings Inc.

Equities

TVGN

US88165K1016

Market Closed - Nasdaq
Other stock markets
 21:30:00 31/05/2024 BST 		5-day change 1st Jan Change
0.8075 USD +4.33% Intraday chart for Tevogen Bio Holdings Inc. -1.52% -92.74%
05-13 Investors Eye Key Inflation Data in Days Ahead as US Futures Trend Modestly Higher Monday MT
05-13 Top Premarket Gainers MT

Press Releases

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Tevogen Bio Reports First Quarter 2024 Financial Results
GL
Tevogen Bio Reports First Quarter 2024 Financial Results
AQ
Tevogen Bio Appoints Former Police Chief & FBI National Academy Graduate, William Keane, as Vice President of Strategic Initiatives
GL
Tevogen Bio Announces Up to $50 Million in Financing to Further Advance Operational Objectives
GL
Tevogen Bio Announces Full Year 2023 Financial Results and Upcoming Operational Objectives
GL
Tevogen Bio CEO Highlights Expected Reporting of a $94.9 Million Liability Elimination, AI Initiative, and Leadership Appointments
GL
Tevogen Bio’s Chief Scientific Officer Speaks on the Harnessing of Cytotoxic T Lymphocytes (CTLs) to Target Cancers
GL
Tevogen Bio Appoints Tapan V Shah as Head of Investor Relations and Corporate Development
GL
Tevogen Bio Reports Series A-1 Preferred Stock Investment at $10 Conversion Price
GL
Tevogen Bio Reports Its Investigational SARS-CoV-2 Specific T Cell Therapy, TVGN-489, Retains Activity Against the Dominant JN.1 Variant
BU
Tevogen Bio Holdings Congratulates its Board Member and Esteemed Global Safety Management Expert, Victor Sordillo, on His appointment as Managing Director of Risk Advisory Services at Verita
BU
Mittul Mehta, Head of Tevogen's Artificial Intelligence Initiative Tevogen.ai, Emphasizes Importance of Proactive Talent Development for Biopharmaceutical Sector to Allow Rapid Adoption of AI
BU
Cell Therapy Company Tevogen Bio Holdings Inc. Prepares to Launch Crucial Genetic Predisposition Study in Preparation to Investigate the Potential of TVGN 489 to Address Critical Unmet Need for Long COVID Treatment
BU
Cell Therapy Company Tevogen Bio Holdings Inc. (Nasdaq: TVGN) Rings Opening Bell at Nasdaq Exchange on February 15th, 2024, Begins Public Trading on the Open Market
BU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. TVGN Stock
  4. News Tevogen Bio Holdings Inc.
  5. Press Releases